Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at firstname.lastname@example.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 05 September 2014 | By Louise Zornoza,
This content is provided by RegLink News, publishers of e-weekly global regulatory news. RegLink offers a 30-day free trial and 15% discount on Global Update subscriptions to RAPS members.
Australia’s Therapeutic Goods Administration (TGA) this week issued a new question and answer (Q&A) guidance concerning the registration process for new prescription drugs, as well as how to make changes to an already registered product that involves clinical, nonclinical or bioequivalence data.
The guidance, released on 3 September 2014, covers a wide range of questions, including one on the use of Section 31 (s.31) questions during the application process.
The consolidated s.31 is a single request for information, which brings together in one document all the questions that have been raised concerning the application from all of the relevant review units of the TGA. If a sponsor needs clarification as to any question in the s.31 document, a written request must be submitted to the TGA.
Tags: Section 31, S.31, Request for Information
Regulatory Focus newsletters
All the biggest regulatory news and happenings.